Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28869611.
- Also identified by DOI 10.1038/nm.4396 and PMC identifier 5719877.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Neutralizing
- Antibodies, Viral
- Lassa Fever